Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 62

1.

Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study.

Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, Sebastiani A, Sanduzzi A, Giunta V, Della Porta R, Bandelli GP, Puglisi S, Tomassetti S, Biffi A, Cerri S, Mari A, Cinetto F, Tirelli F, Farinelli G, Bocchino M, Specchia C, Confalonieri M.

Respir Med. 2015 Apr 25. pii: S0954-6111(15)00121-3. doi: 10.1016/j.rmed.2015.04.010. [Epub ahead of print]

PMID:
25962649
2.

Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.

Nathan SD, du Bois RM, Albera C, Bradford WZ, Costabel U, Kartashov A, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr.

Respir Med. 2015 Apr 24. pii: S0954-6111(15)00119-5. doi: 10.1016/j.rmed.2015.04.008. [Epub ahead of print]

3.

Circulating biomarkers in pulmonary arterial hypertension: update and future direction.

Pezzuto B, Badagliacca R, Poscia R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Volterrani M, Fedele F, Vizza CD.

J Heart Lung Transplant. 2015 Mar;34(3):282-305. doi: 10.1016/j.healun.2014.12.005. Epub 2014 Dec 23.

PMID:
25682555
4.

Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis.

Loeh B, Drakopanagiotakis F, Bandelli GP, von der Beck D, Tello S, Cordani E, Rizza E, Barrocu L, Markart P, Seeger W, Guenther A, Albera C.

Am J Respir Crit Care Med. 2015 Jan 1;191(1):110-3. doi: 10.1164/rccm.201406-1106LE. No abstract available.

PMID:
25551350
5.

Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.

Costabel U, Albera C, Bradford WZ, Hormel P, King TE Jr, Noble PW, Sahn SA, Valeyre D, Du Bois RM.

Sarcoidosis Vasc Diffuse Lung Dis. 2014 Oct 20;31(3):198-205.

PMID:
25363219
6.

'Real-life' information on pulmonary arterial hypertension: the iPHnet Project.

Poscia R, Ghio S, D'Alto M, Vitulo P, Mulè M, Albera C, Parisi F, Badagliacca R, Fedele F, Vizza CD.

Curr Med Res Opin. 2014 Dec;30(12):2409-14. doi: 10.1185/03007995.2014.960514. Epub 2014 Sep 24.

PMID:
25180610
7.

Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis.

Judson MA, Baughman RP, Costabel U, Drent M, Gibson KF, Raghu G, Shigemitsu H, Barney JB, Culver DA, Hamzeh NY, Wijsenbeek MS, Albera C, Huizar I, Agarwal P, Brodmerkel C, Watt R, Barnathan ES.

Eur Respir J. 2014 Nov;44(5):1296-307. doi: 10.1183/09031936.00000914. Epub 2014 Jul 17.

PMID:
25034562
8.

Tumor/stromal caveolin-1 expression patterns in pleural mesothelioma define a subgroup of the epithelial histotype with poorer prognosis.

Righi L, Cavallo MC, Gatti G, Monica V, Rapa I, Busso S, Albera C, Volante M, Scagliotti GV, Papotti M.

Am J Clin Pathol. 2014 Jun;141(6):816-27. doi: 10.1309/AJCP0F6WYBXGVDHX.

PMID:
24838326
9.

Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.

Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, Noble PW, Sahn SA, du Bois RM.

Respirology. 2014 Jul;19(5):740-7. doi: 10.1111/resp.12297. Epub 2014 May 18.

10.

Management of pulmonary arterial hypertension associated to thalassemia: when pulmonary endarterectomy is the best therapeutical option? A case report.

Roggero S, Vullo S, Volpe G, Piga A, Albera C.

J Thromb Thrombolysis. 2015 Jan;39(1):139-43. doi: 10.1007/s11239-014-1073-6.

PMID:
24788071
11.

All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW.

Am J Respir Crit Care Med. 2014 Apr 1;189(7):825-31. doi: 10.1164/rccm.201311-1951OC.

PMID:
24476390
12.

Interferon beta-related nephropathy and interstitial lung disease: a new association and a long-term warning.

Capobianco M, Piccoli G, Neve Vigotti F, Scapoli P, Deagostini MC, Albera C, Roccatello D, Bertolotto A.

Mult Scler. 2014 Jan 20. [Epub ahead of print]

PMID:
24446386
13.

6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.

du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr.

Eur Respir J. 2014 May;43(5):1421-9. doi: 10.1183/09031936.00131813. Epub 2013 Dec 5.

PMID:
24311766
14.

Riociguat for the treatment of pulmonary arterial hypertension.

Ghofrani HA, Galiè N, Grimminger F, Grünig E, Humbert M, Jing ZC, Keogh AM, Langleben D, Kilama MO, Fritsch A, Neuser D, Rubin LJ; PATENT-1 Study Group.

N Engl J Med. 2013 Jul 25;369(4):330-40. doi: 10.1056/NEJMoa1209655.

15.

Where do we stand with IPF treatment?

Albera C, Ferrero C, Rindone E, Zanotto S, Rizza E.

Respir Res. 2013;14 Suppl 1:S7. doi: 10.1186/1465-9921-14-S1-S7. Epub 2013 Apr 16.

16.

Idiopathic pulmonary fibrosis in 2011: key updates on guidelines and therapeutics.

Costabel U, Albera C, Behr J, Cottin V, Guenther A, Richeldi L.

Respir Res. 2013;14 Suppl 1:S1. doi: 10.1186/1465-9921-14-S1-S1. Epub 2013 Apr 16. No abstract available.

17.

Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial.

Raghu G, Million-Rousseau R, Morganti A, Perchenet L, Behr J; MUSIC Study Group.

Eur Respir J. 2013 Dec;42(6):1622-32. doi: 10.1183/09031936.00104612. Epub 2013 May 16.

PMID:
23682110
18.

Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis.

Avouac J, Huscher D, Furst DE, Opitz CF, Distler O, Allanore Y; EPOSS group.

Ann Rheum Dis. 2014 Jan;73(1):191-7. doi: 10.1136/annrheumdis-2012-202567. Epub 2013 Jan 24.

PMID:
23349131
19.

Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good.

Wells AU, Behr J, Costabel U, Cottin V, Poletti V, Richeldi L; European IPF Consensus Group.

Thorax. 2012 Nov;67(11):938-40. doi: 10.1136/thoraxjnl-2012-202580. Epub 2012 Oct 9. No abstract available.

PMID:
23047830
20.

Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.

du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, King TE Jr, Lancaster L, Noble PW, Sahn SA, Thomeer M, Valeyre D, Wells AU.

Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9. doi: 10.1164/rccm.201105-0840OC. Epub 2011 Sep 22.

PMID:
21940789
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk